[go: up one dir, main page]

PE20070456A1 - Sales salicilato y gentisato del compuesto 8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona - Google Patents

Sales salicilato y gentisato del compuesto 8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona

Info

Publication number
PE20070456A1
PE20070456A1 PE2006001090A PE2006001090A PE20070456A1 PE 20070456 A1 PE20070456 A1 PE 20070456A1 PE 2006001090 A PE2006001090 A PE 2006001090A PE 2006001090 A PE2006001090 A PE 2006001090A PE 20070456 A1 PE20070456 A1 PE 20070456A1
Authority
PE
Peru
Prior art keywords
compound
oxazin
ona
piperazin
indol
Prior art date
Application number
PE2006001090A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Kadum Ali
Wendy Dulin
Syed Muzafar Shah
Eric C Ehrsperger
Christopher R Diorio
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37429300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070456A1 publication Critical patent/PE20070456A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: i) UN COMPUESTO DE FORMULA (2) QUE ES SAL SALICILATO DE 8-{4-[3-(5-FLUORO-1H-INDOL-3-IL)-PROPIL]-PIPERAZIN-1-IL}-2-METIL-4H-BENZO[1,4]OXAZIN-3-ONA EN FORMA CRISTALINA QUE TIENE UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE COMPRENDE PICOS EXPRESADOS EN GRADOS 2? DE 7,239; 8,2; 8,999; 10,799; 16,422; 18,03; 19,05; ENTRE OTROS; O ii) UN COMPUESTO DE FORMULA (3) QUE ES SAL GENTISATO DE 8-{4-[3-(5-FLUORO-1H-INDOL-3-IL)-PROPIL]-PIPERAZIN-1-IL}-2-METIL-4H-BENZO[1,4]OXAZIN-3-ONA EN FORMA CRISTALINA QUE TIENE UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE COMPRENDE PICOS EXPRESADOS EN GRADOS 2? DE 8,158; 8,96; 9,923; 10,762; 11,581; 12,701; 13,479; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DEL COMPUESTO (2) Y (3). DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE DOPAMINA D2 E INHIBEN LA RECAPTACION DE SEROTONINA SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, DEPRESION, ANSIEDAD, ENFERMEDAD DE ALZHEIMER
PE2006001090A 2005-09-12 2006-09-11 Sales salicilato y gentisato del compuesto 8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona PE20070456A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71616105P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
PE20070456A1 true PE20070456A1 (es) 2007-06-05

Family

ID=37429300

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001090A PE20070456A1 (es) 2005-09-12 2006-09-11 Sales salicilato y gentisato del compuesto 8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona

Country Status (12)

Country Link
US (1) US7615551B2 (es)
EP (1) EP1940831A1 (es)
JP (1) JP2009507922A (es)
CN (1) CN101263138A (es)
AR (1) AR055423A1 (es)
AU (1) AU2006291059A1 (es)
CA (1) CA2621370A1 (es)
GT (1) GT200600416A (es)
PE (1) PE20070456A1 (es)
RU (1) RU2412184C2 (es)
TW (1) TW200745095A (es)
WO (1) WO2007033192A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800306A (en) * 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US20110065671A1 (en) * 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
SK287018B6 (sk) * 1999-08-23 2009-09-07 Solvay Pharmaceuticals B. V. Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
AU780817B2 (en) 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US7514438B2 (en) * 2003-08-13 2009-04-07 Amgen, Inc. Melanin concentrating hormone receptor antagonist
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof

Also Published As

Publication number Publication date
AR055423A1 (es) 2007-08-22
RU2008114389A (ru) 2009-10-20
TW200745095A (en) 2007-12-16
JP2009507922A (ja) 2009-02-26
CA2621370A1 (en) 2007-03-22
GT200600416A (es) 2007-09-20
CN101263138A (zh) 2008-09-10
US7615551B2 (en) 2009-11-10
EP1940831A1 (en) 2008-07-09
US20070060580A1 (en) 2007-03-15
RU2412184C2 (ru) 2011-02-20
WO2007033192A1 (en) 2007-03-22
AU2006291059A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
UY28374A1 (es) Agentes terapéuticos
UY30812A1 (es) Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
PE20120005A1 (es) Derivados de (2s,3r)-n-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-difluorobenzamida
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
UY28105A1 (es) Derivados de indazol como antagonistas del crf
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal